Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KBP-5074

Small molecule · developed by KBP Biosciences

Phase 3 Most advanced trial (none active)
1 Registered trials

What is KBP-5074?

KBP-5074 is an orally administered tablet drug studied in chronic kidney disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Renal & urology
Developer
KBP Biosciences
In trials of
NVO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
L46509378R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04968184 Phase 3 Chronic Kidney Diseases Terminated NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney Diseases

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.